Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lanreotide · 1 trial · 1 indication
ORR is calculated as the number of people with a complete response (CR) or partial response (PR), divided by the total number of people treated. Complete response is defined as disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. A lower limit of the true ORR will be estimated by the 90% exact lower confidence bound (LCB) for the binomial proportion. A 90% LCB of \< 0.1 will be considered not to be of clinical value. If the 90% LCB is ≥ 0.1, the regimen will be considered efficacious.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Keytruda (pembrolizumab) 200 mg intravenous (IV) infusion every 3 weeks and Somatuline Depot (lanreotide) 90 mg subcutaneous (SQ) injection every 3 weeks. |
| Name | Type | Description |
|---|---|---|
| Lanreotide | DRUG | Somatuline depot (lanreotide) 90 mg SQ every 3 weeks |
| Pembrolizumab | DRUG | Keytruda (pembrolizumab) 200 mg IV every 3 weeks |
Inclusion Criteria: 1. Willing and able to provide written informed consent for the trial. 2. At least 18 years of age on day of signing informed consent. 3. Non-resectable, recurrent, or metastatic well- or moderately-differentiated gastroenteropancreatic neuroendocrine tumor (GEP-NETs) with disea...
Lanreotide is being studied for use in gastroenteropancreatic neuroendocrine tumors, a type of cancer that arises in the digestive system. It is currently in Phase 1 clinical development as an investigational therapy for this condition. The drug is being evaluated in combination with pembrolizumab in a clinical trial.
Lanreotide is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this drug for the treatment of gastroenteropancreatic neuroendocrine tumors. Merck is responsible for the ongoing development and clinical testing of Lanreotide.
Lanreotide is in Phase 1 clinical development for gastroenteropancreatic neuroendocrine tumors. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under investigation for this indication.
Lanreotide has been studied in one clinical trial with the identifier NCT03043664. This Phase 1 trial, titled "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors," was completed in the United States. The trial enrolled 22 participants aged 18 years and older.
Lanreotide is being studied in a biomarker-selected patient population for gastroenteropancreatic neuroendocrine tumors. The clinical trial evaluating Lanreotide used biomarker selection to identify eligible participants. This approach aims to match the drug to patients who may be more likely to respond based on specific biological markers.
Lanreotide is being studied as a depot formulation, as indicated in the clinical trial title "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors." The depot formulation is designed for sustained release of the drug over time. This formulation was used in the Phase 1 trial for this indication.